Company news
Oxford BioDynamics PLC news in 2023
Oxford BioDynamics PLC's news releases, calls and decks from 2023, newest first.
OBD strengths commercial leadership
November 8, 2023
Oxford BioDynamics Plc - Bupa UK to cover EpiSwitch CiRT for customers with cancer
October 19, 2023
Bupa UK to cover EpiSwitch® CiRT for customers
October 18, 2023
Oxford BioDynamics receives reimbursement code for EpiSwitch Prostate Screening Test
October 4, 2023
OBD receives reimbursement code for PSE test
October 3, 2023
Oxford Biodynamics launches the 94% accurate EpiSwitch Prostate Screening blood test for men with prostate cancer risk in the US and UK
September 27, 2023
OBD launches 94% accurate PSE test in US and UK
September 26, 2023
Amendment: Director/PDMR Shareholding
September 1, 2023
Result of General Meeting
August 18, 2023
Results of PrimaryBid Offer
August 4, 2023
Notice of Interim Results and Investor Webinar
May 16, 2023
CiRT expanded validation for ICI immunotherapies
May 15, 2023
US PACT Award for prognosis test for IOrelated HPD
May 2, 2023
Business update for PSE and CiRT tests
April 5, 2023
AIM Rule 17 Schedule 2(g) Update
March 15, 2023
Publication of FY22 Annual Report
March 3, 2023
OBD Prostate Screening EpiSwitch Blood Test Update
February 6, 2023